Episode
Inhaled Insulin for Kids: Inside the INHALE-1 Trial
- Published
- Jun 15, 2026
- Duration seconds
- 2705
- Processing state
not_requested- Canonical source
- https://tcoydthepodcast.transistor.fm/101
Actions
POST https://stenobird.com/v1/public/podcasts/taking-control-of-your-diabetes-the-podcast-5259147/episodes/inhaled-insulin-for-kids-inside-the-inhale-1-trial/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/taking-control-of-your-diabetes-the-podcast-5259147/inhaled-insulin-for-kids-inside-the-inhale-1-trial.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of the TCOYD Podcast, Dr. Edelman and Dr. Pettus are joined by pediatric endocrinologist Dr. Jamie Wood, medical director of pediatric diabetes at Rainbow Babies & Children's Hospital and an investigator on the INHALE-1 trial, to talk through inhaled insulin in kids and where it fits in real-world pediatric care. The conversation focuses on the recent approval of Afrezza for children as young as six, and what the INHALE-1 trial actually showed. Dr. Wood walks through the study design, A1C results, lung-function and safety data, and the practical aspects of dosing inhaled insulin in a pediatric population. Rather than positioning it as a replacement for injections or pumps, the discussion centers on finding the right fit for each child's needs, from the newly diagnosed kid with a needle phobia to the teen trying to dose discreetly during a 20-minute school lunch. Dr. E, Dr. P, and Dr. Wood also discuss the everyday realities that shape how this option is used, including the set-dose cartridge sizes, a titration approach refined in clinic, and how families are mixing and matching tools alongside automated insulin delivery. The takeaway is encouraging: there are more options than ever for managing mealtime insulin in kids, and this one may help fill some of the gaps left by injections and pumps. Key Topics • The recent approval of inhaled insulin for children as young as six • How the INHALE-1 pediatric trial was designed • A1C results and what the primary endpoint analysis showed • Continuous glucose monitor (CGM) metrics across the two groups • Lung-function (FEV1) monitoring and pediatric safety • Weight and body mass index (BMI) findings • Why mealtime dosing is a leading unmet need in pediatric type 1 diabetes (T1D) • The set-dose cartridge approa…